Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

HutchMed's Surufatinib Approved for 2nd Neuroendocrine Tumor Indication

publication date: Jun 21, 2021

Shanghai's HutchMed will launch Sulanda® (surufatinib) in China to treat advanced pancreatic neuroendocrine tumors (pNETs). Surufatinib inhibits angiogenesis (via VEGFR and FGFR), along with a colony stimulating factor-1 receptor (CSF-1R), which promotes microphages in the tumor environment. In patients with pNETs, surufatinib increased median progression-free survival to 10.9 months compared to 3.7 months for the placebo group. In December 2020, surufatinib was first approved for advanced extra-pancreatic (non-pancreatic) neuroendocrine tumors. More details....

Stock Symbols: (NSDQ/AIM: HCM)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.